½ÃÀ庸°í¼­
»óǰÄÚµå
1571600

¾Ï µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : ¼ÒÇÁÆ®¿þ¾îº°, Àü°³ ¸ðµ¨º°, ±¸¼º¿ä¼Òº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)

Cancer Registry Software Market Size, Share & Trends Analysis Report By Software (Standalone), By Deployment model (On-premise), By Component (Commercial), By End-use, By Region, And Segment Forecasts, 2024 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 100 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¾Ï µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ¼ºÀå°ú µ¿Çâ:

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°è ¾Ï µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ±Ô¸ð´Â 2024³âºÎÅÍ 2030³â±îÁö 12.7%ÀÇ CAGRÀ» ±â·ÏÇÏ¿© 2030³â¿¡´Â 1¾ï 7,240¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾Ï ¹ßº´·üÀÇ Áõ°¡´Â ¿¹Ãø ±â°£ µ¿¾È ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÇöÀç ¾ÏÀº Àü ¼¼°è »ç¸Á ¿øÀÎ Áß 2À§¸¦ Â÷ÁöÇϰí ÀÖÀ¸¸ç, WHO¿¡ µû¸£¸é »ç¸ÁÀÚÀÇ ¾à 70%°¡ ÁßÀú¼Òµæ ±¹°¡¿¡¼­ ¹ß»ýÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ¼±Áø±¹ÀÇ ÀüÀڰǰ­±â·Ï(EHR) äÅ÷ü Áõ°¡¿Í ½ÃÆÇ ÈÄ Á¶»ç¸¦ À§ÇÑ ¾Ï µî·Ï¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ÇâÈÄ ¸î ³â µ¿¾È ¾Ï µî·Ï ¼ÒÇÁÆ®¿þ¾îÀÇ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµÇ´Â ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ½ÃÀå ±â¾÷µéÀº º¸¾È À§ÇèÀ» ÃÖ¼ÒÈ­Çϰí È¿À²ÀûÀÎ ¼ÒÇÁÆ®¿þ¾î¸¦ Á¦°øÇϱâ À§ÇØ Áö¼ÓÀûÀ¸·Î ¼ÒÇÁÆ®¿þ¾î¸¦ ¾÷µ¥ÀÌÆ®Çϰí ÀÖÀ¸¸ç, ÀÌ·Î ÀÎÇØ ½ÃÀå ÀÎÁöµµ¿Í äÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2018³â 4¿ù Elekta´Â MOSAIQ Oncology Information System ¼ÒÇÁÆ®¿þ¾î¸¦ °³¼±Çϱâ À§ÇØ PalabraApps LLC¿¡ ÅõÀÚÇß½À´Ï´Ù.

´ëÇü Á¦¾à»ç ¹× »ý¸í°øÇÐ ±â¾÷ÀÌ ¼öÇàÇÏ´Â ÀÓ»ó½ÃÇèÀÇ ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È ½ÃÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾Ï µî·Ï µ¥ÀÌÅÍ´Â ÀÓ»ó½ÃÇèÀ» À§ÇÑ È¯ÀÚ ÃßÀû¿¡ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ, ÀÌ ¼ÒÇÁÆ®¿þ¾î¸¦ »ç¿ëÇÏ¸é Æ¯Á¤ À¯ÇüÀÇ ¾Ï¿¡ °É¸° ºÎÀ§¸¦ ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. ´ëÇü Á¦¾à»çµéÀº ³»ºÎ Á÷¿ø Çʿ伺ÀÌ Àû°í, ºñ¿ë È¿À²¼ºÀÌ ³ôÀ¸¸ç, ÀÚ¿øÀ» È¿À²ÀûÀ¸·Î °ü¸®ÇÒ ¼ö ÀÖ´Ù´Â ÀÌÀ¯·Î ¾Ï µî·Ï ¼ÒÇÁÆ®¿þ¾î¸¦ Á¡Á¡ ´õ ¼±È£Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ¼ºÀåÀÇ ÆøÀ» ´õ¿í ³ÐÈ÷°í ÀÖ½À´Ï´Ù.

¾Ï µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • µ¶¸³Çü ¼ÒÇÁÆ®¿þ¾î°¡ 2023³â 80.8%ÀÇ Á¡À¯À²À» Â÷ÁöÇÏ¸ç ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù.
  • ±¸Ãà ¸ðµ¨º°·Î´Â ¿ÂÇÁ·¹¹Ì½º ¸ðµ¨ÀÌ 2023³â 59.8%ÀÇ Á¡À¯À²À» Â÷ÁöÇÏ¸ç ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù.
  • ±¸¼º¿ä¼Òº°·Î´Â »ó¾÷¿ë ºÎ¹®ÀÌ 2023³â 75.0%ÀÇ Á¡À¯À²À» Â÷ÁöÇÏ¸ç ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù.
  • Á¤ºÎ ¹× Á¦3ÀÚ ºÎ¹®ÀÌ 2023³â 27.2%ÀÇ Á¡À¯À²À» Â÷ÁöÇÏ¸ç ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù.
  • ºÏ¹Ì ¾Ï µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀº 2023³â 44.0%ÀÇ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¹Ãø ±â°£ µ¿¾È 14.8%ÀÇ CAGR·Î °¡Àå ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾Ï µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå ¼Ò°³/°èÅë Àü¸Á
  • ½ÃÀå ±Ô¸ð¿Í ¼ºÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ¾Ï µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ºÐ¼® Åø
    • Porters ºÐ¼®
    • PESTEL ºÐ¼®

Á¦4Àå ¾Ï µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀå : ¼ÒÇÁÆ®¿þ¾îº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¾Ï µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀå : ¼ÒÇÁÆ®¿þ¾îº° º¯µ¿ ºÐ¼®, 2023³â ¹× 2030³â
  • µ¶¸³Çü
  • ÅëÇÕÇü

Á¦5Àå ¾Ï µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀå : Àü°³ ¸ðµ¨º° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¾Ï µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀå : Àü°³ ¸ðµ¨º° º¯µ¿ ºÐ¼®, 2023³â ¹× 2030³â
  • ¿ÂÇÁ·¹¹Ì½º
  • Ŭ¶ó¿ìµå ±â¹Ý

Á¦6Àå ¾Ï µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀå : ±¸¼º¿ä¼Òº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¾Ï µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀå : ±¸¼º¿ä¼Òº° º¯µ¿ ºÐ¼®, 2023³â ¹× 2030³â
  • »ó¾÷
  • °ø°ø

Á¦7Àå ¾Ï µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¾Ï µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀå : ÃÖÁ¾ ¿ëµµº° º¯µ¿ ºÐ¼®, 2023³â ¹× 2030³â
  • Á¤ºÎ ¹× Á¦3ÀÚ
  • ¹Î°£ º¸Çèȸ»ç
  • º´¿ø ¹× ÀÇ·á ÇàÀ§
  • Á¦¾à ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ¹× ÀÇ·á±â±â ±â¾÷
  • ¿¬±¸±â°ü

Á¦8Àå ¾Ï µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀå : Áö¿ªº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ¾Ï µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀå Á¡À¯À² : Áö¿ªº°, 2023³â ¹× 2030³â
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • µ§¸¶Å©
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • Äí¿þÀÌÆ®

Á¦9Àå °æÀï »óȲ

  • ÁÖ¿ä ½ÃÀå ÁøÃâ ±â¾÷ÀÇ ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®
  • ±â¾÷ ºÐ·ù
  • ±â¾÷ È÷Æ®¸Ê ºÐ¼®
  • ±â¾÷ °³¿ä
    • Elekta
    • Oracle
    • ONCO, Inc.
    • IBM
    • MCKESSON CORPORATION
    • Conduent, Inc.
    • Ordinate Corporation
    • Volpara Health Limited
    • Health Catalyst
    • Rocky Mountain Cancer Data Systems(RMCDS)(University of Utah Health)
ksm 24.11.05

Cancer Registry Software Market Growth & Trends:

The global cancer registry software market size is expected to reach USD 172.4 million by 2030, registering a CAGR of 12.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. Growing incidence of cancer is expected to aid growth over the forecast period. Currently, cancer is the second leading cause of death globally, and according to WHO, around 70% of the deaths occur in low- and middle-income countries.

Moreover, rising adoption of Electronic Health Records (EHRs) in developed countries and increasing need for cancer registries for post-marketing surveillance are among the factors further anticipated to boost the demand for cancer registry software in the coming years. Market players are constantly involved in software updation in an attempt to minimize security risks and provide efficient software, thereby increasing market visibility and adoption. For instance, in April 2018, Elekta invested in PalabraApps LLC to improve its MOSAIQ Oncology Information System software.

Increasing number of clinical trials being conducted by major pharmaceutical and biotechnological companies is expected to drive the market over the forecast period. Cancer registry data helps in tracking patients for clinical trials. Moreover, the affected locations for any specific type of cancer can be identified by using this software. Major pharmaceutical companies are increasingly preferring cancer registry software owing to less requirement of internal staff, increased cost-effectiveness, and efficient management of resources, which is further widening the scope for growth.

Cancer Registry Software Market Report Highlights:

  • Standalone software dominated the market and accounted for a share of 80.8% in 2023 attributed to its advanced features and easy-to-use tools.
  • On the basis of deployment model, on-premise model segment dominated the market and accounted for a share of 59.8% in 2023.
  • On the basis of components, the commercial segment dominated the market and accounted for a share of 75.0% in 2023 owing to its advantage of data safety as compared to the public database.
  • The government & third-party segment dominated the market and accounted for a share of 27.2% in 2023.
  • North America cancer registry software market accounted for the largest revenue share of 44.0% in 2023, owing to the presence of developed infrastructure.
  • The Asia Pacific is expected to grow at the fastest CAGR of 14.8% over the forecast period, owing to increasing government initiatives in this region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Cancer Registry Software Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Cancer Registry Software Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Cancer Registry Software Market: Software Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Cancer Registry Software Market: Software Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Standalone
    • 4.3.1. Standalone Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Integrated
    • 4.4.1. Integrated Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Cancer Registry Software Market: Deployment Model Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Cancer Registry Software Market: Deployment Model Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. On-premise
    • 5.3.1. On-premise Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Cloud Based
    • 5.4.1. Cloud Based Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Cancer Registry Software Market: Component Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Cancer Registry Software Market: Component Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Commercial
    • 6.3.1. Commercial Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Public
    • 6.4.1. Public Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Cancer Registry Software Market: End-use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Cancer Registry Software Market: End-use Movement Analysis, 2023 & 2030 (USD Million)
  • 7.3. Government & Third Party
    • 7.3.1. Government & Third-Party Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Private Payers
    • 7.4.1. Private Payers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Hospital & Medical Practice
    • 7.5.1. Hospital & Medical Practice Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Pharma Biotech & Medical Device Companies
    • 7.6.1. Pharma Biotech & Medical Device Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Research Institutes
    • 7.7.1. Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Cancer Registry Software Market: Regional Estimates & Trend Analysis

  • 8.1. Cancer Registry Software Market Share, By Region, 2023 & 2030, USD Million
  • 8.2. North America
    • 8.2.1. North America Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Canada Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.4. Mexico
      • 8.2.4.1. Mexico Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. UK Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Germany Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. France Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Italy Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Spain Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Denmark Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Sweden Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Norway Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Japan Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. China Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. India Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.5. Australia
      • 8.4.5.1. Australia Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.6. South Korea
      • 8.4.6.1. South Korea Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.7. Thailand
      • 8.4.7.1. Thailand Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Brazil Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Argentina
      • 8.5.3.1. Argentina Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Middle East and Africa
    • 8.6.1. Middle East and Africa Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. South Africa Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Saudi Arabia Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. UAE Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Kuwait Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis by Key Market Participants
  • 9.2. Company Categorization
  • 9.3. Company Heat Map Analysis
  • 9.4. Company Profiles
    • 9.4.1. Elekta
      • 9.4.1.1. Participant's Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Recent Developments/ Strategic Initiatives
    • 9.4.2. Oracle
      • 9.4.2.1. Participant's Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Recent Developments/ Strategic Initiatives
    • 9.4.3. ONCO, Inc.
      • 9.4.3.1. Participant's Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Recent Developments/ Strategic Initiatives
    • 9.4.4. IBM
      • 9.4.4.1. Participant's Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Recent Developments/ Strategic Initiatives
    • 9.4.5. MCKESSON CORPORATION
      • 9.4.5.1. Participant's Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Recent Developments/ Strategic Initiatives
    • 9.4.6. Conduent, Inc.
      • 9.4.6.1. Participant's Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Recent Developments/ Strategic Initiatives
    • 9.4.7. Ordinate Corporation
      • 9.4.7.1. Participant's Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Recent Developments/ Strategic Initiatives
    • 9.4.8. Volpara Health Limited
      • 9.4.8.1. Participant's Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Recent Developments/ Strategic Initiatives
    • 9.4.9. Health Catalyst
      • 9.4.9.1. Participant's Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Recent Developments/ Strategic Initiatives
    • 9.4.10. Rocky Mountain Cancer Data Systems (RMCDS) (University of Utah Health)
      • 9.4.10.1. Participant's Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Recent Developments/ Strategic Initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦